Genesis Healthcare, Inc. (GEN) Downgraded to “Strong Sell” at ValuEngine
Genesis Healthcare, Inc. (NYSE:GEN) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday, July 13th.
Separately, Cantor Fitzgerald began coverage on Genesis Healthcare in a research report on Wednesday, July 5th. They set an “overweight” rating on the stock. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. Genesis Healthcare presently has an average rating of “Hold” and a consensus target price of $2.65.
Genesis Healthcare (NYSE:GEN) opened at 1.41 on Thursday. The firm’s 50-day moving average is $1.62 and its 200-day moving average is $2.52. Genesis Healthcare has a 1-year low of $1.38 and a 1-year high of $4.75. The company’s market capitalization is $130.75 million.
Genesis Healthcare (NYSE:GEN) last announced its quarterly earnings data on Tuesday, May 9th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.25. Genesis Healthcare had a negative net margin of 1.27% and a negative return on equity of 0.81%. The firm had revenue of $1.39 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the business posted ($0.48) EPS. Equities research analysts predict that Genesis Healthcare will post ($1.27) EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in the stock. Columbia Pacific Advisors LLC raised its stake in Genesis Healthcare by 38.6% in the first quarter. Columbia Pacific Advisors LLC now owns 5,294,819 shares of the company’s stock worth $13,978,000 after buying an additional 1,475,508 shares during the last quarter. First Washington CORP raised its stake in Genesis Healthcare by 15.9% in the first quarter. First Washington CORP now owns 1,457,820 shares of the company’s stock worth $3,849,000 after buying an additional 199,900 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Genesis Healthcare by 500.3% in the first quarter. JPMorgan Chase & Co. now owns 1,026,169 shares of the company’s stock valued at $2,709,000 after buying an additional 855,240 shares during the last quarter. State Street Corp boosted its position in Genesis Healthcare by 15.7% in the fourth quarter. State Street Corp now owns 734,589 shares of the company’s stock valued at $3,124,000 after buying an additional 99,474 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Genesis Healthcare by 116.3% in the first quarter. Renaissance Technologies LLC now owns 687,000 shares of the company’s stock valued at $1,814,000 after buying an additional 369,400 shares during the last quarter. Institutional investors own 14.37% of the company’s stock.
About Genesis Healthcare
Genesis Healthcare, Inc is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Genesis Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genesis Healthcare Inc. and related stocks with our FREE daily email newsletter.